Alps Makes Advanced Medicine Affordable for All

Strategically situated among the bustling business hub and commercial districts of Kuala Lumpur, Malaysia, Alps Global Holding Berhad (“Alps”) is a fully-integrated biotechnology research, medical and wellness company dedicated to the development of personalised medicine using cutting-edge technologies such as genomics DNA, mRNA, and cellular therapy to usher in a new era of healthcare advancement.

Dedicated to making advanced healthcare accessible to all, Alps has forged collaborations with like-minded clinicians, stakeholders, corporations, scientists and researchers. Alps envisions a future where enhanced quality of life is achieved through precision and preventive healthcare solutions.

Alps is consistently pushing the boundaries of research and development in innovative areas of life sciences – cell and gene therapy products (CGTP), notably in:

• Umbilical Cord Mesenchymal Stem Cells for Diabetes and Lung Fibrosis
• Induced Pluripotent Stem Cells (iPSCs) for Cardiomyocyte regeneration
• Natural Killer Cells for solid tumour cancers
• mRNA Vaccines (Current: Covid-19, future: Personalised anti-cancer vaccine HPV vaccine, Flu vaccine and Influenza A & B vaccine)
• Car-T for lymphoma and leukaemia

At the heart of Alps’ ecosystem are its core centres: Alps Medical Centre, Alps Wellness Centre, MyGenome Sdn. Bhd.- a Bionexus accredited Molecular Institute (full fledged whole genome sequencing and mRNA technologies) and Celestialab Sdn. Bhd. – a current good manufacturing practice (“cGMP”) accredited cell manufacturing lab with approval for tax incentive – Pioneer Status. Each centre embodies a shared philosophy and ethos dedicated to revitalising the health and well-being of individuals.

Supported by various Government facilitations, Alps is empowered to drive innovative research and development, significantly contributing to the biotechnology landscape. With a determination to lead the healthcare industry towards a brighter future, Alps is establishing an all-encompassing supply chain ecosystem. This initiative aims to foster biotechnology advancement in Southeast Asia while positioning Alps as a global research epicentre for cutting-edge healthcare solutions.

By transforming conceptualisation into reality, Alps has an unyielding aspiration to become the key driving force in spearheading and expanding the progression in the development of reliable and affordable medicine for all.

Alps’ recent merger with a publicly traded special purpose acquisition company has propelled it onto the global stage, increasing its enterprise value to approximately USD1.6 billion. As it prepares for listing on Nasdaq, Alps remains committed to sustainability and global collaboration in biotechnology. With a shared vision for a healthier tomorrow, Alps envisions a future where biotechnology companies will unite in their dedication to humanity’s well-being.